137 related articles for article (PubMed ID: 17438713)
1. 111In-pentetreotide scintigraphy in medulloblastoma: a comparison with magnetic resonance imaging.
Yüksel M; Lutterbey G; Biersack HJ; Elke U; Hasan C; Gao Z; Bode U; Ezziddin S
Acta Oncol; 2007; 46(1):111-7. PubMed ID: 17438713
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
3. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
5. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI.
Lee JD; Kim DI; Lee JT; Chang JW; Park CY
J Nucl Med; 1995 Apr; 36(4):537-41. PubMed ID: 7699438
[TBL] [Abstract][Full Text] [Related]
6. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
7. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma.
Müller HL; Frühwald MC; Scheubeck M; Rendl J; Warmuth-Metz M; Sörensen N; Kühl J; Reubi JC
J Neurooncol; 1998 May; 38(1):27-40. PubMed ID: 9540055
[TBL] [Abstract][Full Text] [Related]
8. 111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging.
Schillaci O; Massa R; Scopinaro F
J Nucl Med; 2000 Mar; 41(3):459-62. PubMed ID: 10716319
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies.
Khanna G; O'Dorisio MS; Menda Y; Glasier C; Deyoung B; Smith BJ; Graham M; Juweid M
Pediatr Blood Cancer; 2008 Mar; 50(3):561-6. PubMed ID: 17387742
[TBL] [Abstract][Full Text] [Related]
10. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
11. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
Rostomily RC; Elias M; Deng M; Elias P; Born DE; Muballe D; Silbergeld DL; Futran N; Weymuller EA; Mankoff DA; Eary J
Head Neck; 2006 Apr; 28(4):305-12. PubMed ID: 16470879
[TBL] [Abstract][Full Text] [Related]
13. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic value of somatostatin receptor scintigraphy with indium-111 pentetreotide in small-cell bronchial carcinoma].
Hoefer M; Schmidt S; Welter J; Kirsch CM; Ukena D; Sybrecht GW
Pneumologie; 1998 Feb; 52(2):106-12. PubMed ID: 9557059
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma.
Klutmann S; Bohuslavizki KH; Brenner W; Behnke A; Tietje N; Kröger S; Hugo HH; Mehdorn HM; Clausen M; Henze E
J Nucl Med; 1998 Nov; 39(11):1913-7. PubMed ID: 9829583
[TBL] [Abstract][Full Text] [Related]
16. Single photon emission computerized tomography increases the sensitivity of indium-111-pentetreotide scintigraphy in detecting abdominal carcinoids.
Schillaci O; Scopinaro F; Danieli R; Angeletti S; Tavolaro R; Annibale B; Cannas P; Marignani M; Colella AC; Delle Fave G
Anticancer Res; 1997; 17(3B):1753-6. PubMed ID: 9179229
[TBL] [Abstract][Full Text] [Related]
17. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography].
Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669
[TBL] [Abstract][Full Text] [Related]
18. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
Nauck C; Ivancević V; Emrich D; Creutzfeldt W
Z Gastroenterol; 1994 Jun; 32(6):323-7. PubMed ID: 7975760
[TBL] [Abstract][Full Text] [Related]
19. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
20. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
